

Piotr Wiland

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2393874/piotr-wiland-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

60
papers

1,271
citations

17
h-index

35
g-index

67
ext. papers

1,668
ext. citations

3.2
avg, IF

4.29
L-index

#	Paper	IF	Citations
60	Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS). <i>BioDrugs</i> , 2021 , 35, 229-238	7.9	2
59	Is it possible to not perform salivary gland biopsy in targeted patients according to unstimulated salivary flow results in patients with suspected Sjögren's syndrome?. <i>Rheumatology International</i> , 2021 , 41, 1125-1131	3.6	1
58	Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomised study in rheumatoid arthritis. <i>Rheumatology</i> , 2021 ,	3.9	4
57	Management of rheumatoid arthritis in Poland - where daily practice might not always meet evidence-based guidelines. <i>Archives of Medical Science</i> , 2021 , 17, 1286-1293	2.9	1
56	Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial. <i>Rheumatology</i> , 2021 , 60, 2277-2287	3.9	14
55	Brainstem auditory evoked potentials in patients with primary Sjögren's syndrome without central nervous system involvement. <i>Clinical Rheumatology</i> , 2021 , 40, 991-997	3.9	1
54	Relationship Between Interleukin-6 -174G/C Genetic Variant and Efficacy of Methotrexate Treatment in Psoriatic Arthritis Patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2021 , 14, 157-166 ^{2.1}	2.1	1
53	Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. <i>Arthritis Research and Therapy</i> , 2021 , 23, 51	5.7	11
52	Differences in clinical phenotypes of primary Sjögren's syndrome depending on early or late onset. <i>Advances in Clinical and Experimental Medicine</i> , 2021 , 30, 1141-1146	1.8	0
51	Association of MICA-129Met/Val polymorphism with clinical outcome of anti-TNF therapy and MICA serum levels in patients with rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , 2020 , 20, 760-769	3.5	4
50	CD4CD28 T cells are expanded in moderately active systemic lupus erythematosus and secrete pro-inflammatory interferon gamma, depending on the Disease Activity Index. <i>Lupus</i> , 2020 , 29, 705-714 ^{2.6}	2.6	7
49	Ormond's disease accompanied by ankylosing spondylitis - a case report. <i>Pomeranian Journal of Life Sciences</i> , 2020 , 66, 16-20	0.1	
48	Prevalence and clinical presentation of lymphoproliferative disorder in patients with primary Sjögren's syndrome. <i>Rheumatology International</i> , 2020 , 40, 399-404	3.6	6
47	Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome. <i>Rheumatology</i> , 2020 , 59, 2350-2359	3.9	24
46	Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study. <i>BioDrugs</i> , 2020 , 34, 809-823	7.9	10
45	Pathophysiology of hyperuricemia and its clinical significance - a narrative review. <i>Reumatologia</i> , 2020 , 58, 312-323	1.7	10
44	Autoimmune congenital heart block and primary Sjögren's syndrome: characterisation and outcomes of 49 cases. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 126, 95-102	2.2	2

43	Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial. <i>Rheumatology</i> , 2019 , 58, 2193-2202	3.9	22
42	Comorbidity burden and clinical characteristics of patients with difficult-to-control rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2019 , 38, 2473-2481	3.9	12
41	The effect of LILRB1 but not LILRA3 gene polymorphism in immunopathology of ankylosing spondylitis-A parallel to KIR genes. <i>International Journal of Immunogenetics</i> , 2019 , 46, 146-151	2.3	2
40	Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results From a Randomized Phase III Trial. <i>BioDrugs</i> , 2019 , 33, 79-91	7.9	15
39	Prevalence and clinical characteristics of rheumatoid arthritis in Poland: a nationwide study. <i>Archives of Medical Science</i> , 2019 , 15, 134-140	2.9	15
38	Cognitive impairment, event-related potentials and immunological status in patients with systemic lupus erythematosus. <i>Advances in Clinical and Experimental Medicine</i> , 2019 , 28, 185-192	1.8	6
37	Classification criteria for secondary Sjögren's syndrome. Current state of knowledge. <i>Reumatologia</i> , 2019 , 57, 277-280	1.7	10
36	Autoantibody and metalloproteinase activity in early arthritis. <i>Clinical Rheumatology</i> , 2019 , 38, 827-834	3.9	3
35	Immunohistochemical and ultrastructural analysis of sporadic inclusion body myositis: a case series. <i>Rheumatology International</i> , 2019 , 39, 1291-1301	3.6	4
34	The variety of clinical presentations in IgG4-related disease in Rheumatology. <i>Rheumatology International</i> , 2018 , 38, 303-309	3.6	6
33	How to Distinguish Patients with pSS among Individuals with Dryness without Invasive Diagnostic Studies. <i>Journal of Immunology Research</i> , 2018 , 2018, 1060421	4.5	
32	Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis. <i>Genes</i> , 2018 , 9,	4.2	9
31	Addendum: Iwaszko et al., Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis. <i>Genes</i> 2018, 9, 64. <i>Genes</i> , 2018 , 9, 94	4.2	78
30	Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial. <i>MAbs</i> , 2018 , 10, 934-943	6.6	36
29	Methotrexate treatment for rheumatoid arthritis in Poland: Retrospective analysis of patients in routine clinical practice. <i>Reumatologia</i> , 2018 , 56, 3-9	1.7	3
28	Satisfaction and discontent of Polish patients with biological therapy of rheumatic diseases: results of a multi-center questionnaire study. <i>Reumatologia</i> , 2018 , 56, 140-148	1.7	1
27	Systemic Lupus Erythematosus Induced by Autoimmune/ Inflammatory Syndrome Induced by Adjuvants. Is it Possible? Long-Term Follow-up and Literature Review. <i>Archives of Rheumatology</i> , 2018 , 33, 247-249	0.9	
26	Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology. <i>Reumatologia</i> , 2018 , 56, 203-211	1.7	11

25	Biosimilar switching - current state of knowledge. <i>Reumatologia</i> , 2018 , 56, 234-242	1.7	24
24	Parameters of Somatosensory Evoked Potentials in Patients with Primary Sjögren's Syndrome: Preliminary Results. <i>Journal of Immunology Research</i> , 2018 , 2018, 8174340	4.5	2
23	Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 355-363	2.4	190
22	EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 491-496	2.4	125
21	Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 346-354	2.4	161
20	Antibodies against monomeric C-reactive protein - a promising biomarker of lupus nephritis?. <i>Clinical Biochemistry</i> , 2017 , 50, 756-762	3.5	5
19	Dr. Wiland, et al, reply. <i>Journal of Rheumatology</i> , 2017 , 44, 259	4.1	
18	The role of microRNA-5196 in the pathogenesis of systemic sclerosis. <i>European Journal of Clinical Investigation</i> , 2017 , 47, 555-564	4.6	20
17	Results from Polish Spondyloarthritis Initiative registry (PolSPI) - methodology and data from - the first year of observation. <i>Reumatologia</i> , 2017 , 55, 59-64	1.7	
16	Polymorphisms within Genes Involved in Regulation of the NF- κ B Pathway in Patients with Rheumatoid Arthritis. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	20
15	Chest HRCT findings in patients with primary Sjögren's syndrome. <i>Advances in Clinical and Experimental Medicine</i> , 2017 , 26, 1101-1106	1.8	7
14	The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2016 , 43, 1268-77	4.1	13
13	Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment. <i>Joint Bone Spine</i> , 2016 , 83, 75-9	2.9	6
12	The Safety of Intravenous Cyclophosphamide in the Treatment of Rheumatic Diseases. <i>Advances in Clinical and Experimental Medicine</i> , 2016 , 25, 479-84	1.8	7
11	Disease Activity, Oxidized-LDL Fraction and Anti-Oxidized LDL Antibodies Influence Cardiovascular Risk in Rheumatoid Arthritis. <i>Advances in Clinical and Experimental Medicine</i> , 2016 , 25, 43-50	1.8	19
10	The Activity of JAK/STAT and NF- κ B in Patients with Rheumatoid Arthritis. <i>Advances in Clinical and Experimental Medicine</i> , 2016 , 25, 709-17	1.8	23
9	Assessment of the Effect of Methotrexate Therapy on Bone Metabolism in Patients with Rheumatoid Arthritis. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2015 , 63, 397-404	4	18
8	Analysis of associations between polymorphisms within genes coding for tumour necrosis factor (TNF)-alpha and TNF receptors and responsiveness to TNF-alpha blockers in patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2015 , 82, 94-9	2.9	34

7	MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1058-64	2.4	106
6	Pregnancy exacerbates complications of acquired hemophilia in a patient with systemic lupus erythematosus. <i>Postepy Dermatologii I Alergologii</i> , 2015 , 32, 235-8	1.5	2
5	Cytokine profiles in axial spondyloarthritis. <i>Reumatologia</i> , 2015 , 53, 9-13	1.7	9
4	Reported concepts for the treatment modalities and pain management of temporomandibular disorders. <i>Journal of Headache and Pain</i> , 2015 , 16, 106	8.8	109
3	Activity of JAK/STAT and NF-kB in patients with axial spondyloarthritis. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2015 , 69, 1291-8	0.3	5
2	Significance of association of HLA-C and HLA-E with psoriatic arthritis. <i>Human Immunology</i> , 2014 , 75, 1188-91	2.3	9
1	Inclusion body myositis associated with Sjögren's syndrome. <i>Rheumatology International</i> , 2013 , 33, 3083-6	3.6	23